Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
3billion | RCV001807916 | SCV002058194 | pathogenic | Alagille syndrome due to a JAG1 point mutation | 2022-01-03 | criteria provided, single submitter | clinical testing | Stop-gained (nonsense): predicted to result in a loss or disruption of normal protein function through nonsense-mediated decay (NMD) or protein truncation. Multiple pathogenic variants are reported downstream of the variant (PVS1_VS). It is not observed in the gnomAD v2.1.1 dataset (PM2_M). The variant has been reported to be associated with JAG1 related disorder (PMID:17241866).Therefore, this variant is classified as pathogenic according to the recommendation of ACMG/AMP guideline. |
Labcorp Genetics |
RCV001807916 | SCV002238964 | pathogenic | Alagille syndrome due to a JAG1 point mutation | 2021-11-04 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Gln884*) in the JAG1 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in JAG1 are known to be pathogenic (PMID: 11180599). For these reasons, this variant has been classified as Pathogenic. This premature translational stop signal has been observed in individual(s) with Alagille syndrome (PMID: 17241866). This variant is not present in population databases (gnomAD no frequency). |